Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
More than 850 million people worldwide suffer from some form of kidney disease. This includes those with chronic kidney disease (CKD), which is when the kidneys are damaged and progressively fail, and acute kidney injury (AKI), which is a rapid loss of kidney function over a short period of time.
In the US alone, there are 37 million patients suffering from CKD vs. 17 million cancer patients
This is more than 20X the number of people with cancer (44 million) or HIV/AIDS (38 million) worldwide
This is 2X the number of diabetes patients (422 million)
1 in 5
Adults suffer from AKI during a hospital stay